3.4 Opioids, Opioid Toxidrome, and Naloxone Titration
Key Takeaways
- The opioid toxidrome is respiratory depression plus central nervous system depression plus miosis, and the respiratory rate and tidal volume, not the pupils, define severity.
- Naloxone is titrated to adequate spontaneous ventilation rather than full alertness, starting at 0.04 to 0.4 mg intravenously in a dependent adult and 0.1 mg/kg in a child, because abrupt reversal causes agitation, vomiting, and pulmonary edema.
- Naloxone lasts 30 to 90 minutes while methadone, buprenorphine, extended-release oxycodone, and many fentanyl analogues last far longer, so re-sedation is expected and an infusion set near two-thirds of the effective waking dose per hour is used.
- Agent-specific hazards include methadone QT prolongation and torsades, tramadol and meperidine seizures, loperamide cardiac conduction and QT effects at abuse doses, diphenhydramine-like anticholinergic findings with diphenoxylate-atropine, and delayed apnea in toddlers exposed to buprenorphine films or discarded fentanyl patches.
- A negative routine opiate immunoassay never excludes fentanyl, methadone, buprenorphine, tramadol, or a novel synthetic opioid, because the assay is calibrated to morphine.
Opioids bind mu, kappa, and delta receptors coupled to inhibitory G proteins. Activation closes voltage-gated calcium channels presynaptically, opens potassium channels postsynaptically, and reduces cyclic adenosine monophosphate, which together suppress neurotransmitter release. The clinically decisive effect is at the brainstem, where mu agonism blunts the medullary response to rising carbon dioxide and, at higher doses, abolishes the hypoxic drive.
The Cardinal Triad and Its Exceptions
Triad: central nervous system depression, respiratory depression (rate below about 10 to 12 breaths per minute or shallow tidal volume), and miosis.
Additional expected findings are bradycardia, hypotension, hypothermia, decreased bowel sounds, and non-cardiogenic pulmonary edema with high-potency or injected opioids.
| Exception | Explanation |
|---|---|
| Normal or dilated pupils | Meperidine (normeperidine), propoxyphene, tramadol, severe hypoxia or acidosis, co-ingested sympathomimetic or antimuscarinic |
| Seizures | Tramadol, meperidine, propoxyphene; also hypoxia from any opioid |
| Wide QRS | Propoxyphene, loperamide at abuse doses |
| Prolonged QT with torsades | Methadone, loperamide |
| Agitation rather than sedation | Withdrawal after naloxone, or a stimulant co-ingestant |
| Anticholinergic signs in a child | Diphenoxylate-atropine (Lomotil) |
Clinical anchor: the respiratory rate is the vital sign that kills. A patient with pinpoint pupils breathing 16 times a minute needs observation; a patient breathing 6 times a minute needs ventilation and naloxone now.
Agent-Specific Hazards
| Opioid | Distinguishing Feature | Practical Consequence |
|---|---|---|
| Methadone | Half-life 15 to 60 hours; blocks the delayed rectifier potassium current | Very prolonged apnea risk, QT prolongation and torsades; admit and monitor for 24 hours or more |
| Buprenorphine | Partial mu agonist with high receptor affinity and a ceiling on respiratory depression in adults | Relatively safe in tolerant adults, but films and tablets cause delayed, prolonged respiratory depression in toddlers; reversal may need larger naloxone doses |
| Fentanyl and analogues | High potency, rapid onset, lipophilic; carfentanil and nitazenes are far more potent | Chest wall rigidity, rapid arrest, and repeat naloxone dosing; patches (including discarded ones) are a pediatric hazard |
| Tramadol | Weak mu agonist plus serotonin and norepinephrine reuptake inhibition | Seizures at therapeutic and overdose levels, serotonin toxicity, only partially naloxone-responsive |
| Meperidine | Metabolite normeperidine accumulates, especially in kidney failure | Tremor, myoclonus, seizures; naloxone does not reverse normeperidine neuroexcitation |
| Loperamide | Peripherally restricted at label doses; abused at doses of hundreds of milligrams a day to self-treat withdrawal | Wide QRS, marked QT prolongation, torsades, cardiac arrest; treat with sodium bicarbonate, magnesium, and overdrive pacing as needed |
| Diphenoxylate-atropine | Two toxins in one tablet | Early anticholinergic phase, then delayed (up to 12 to 24 hours) opioid apnea in children |
| Codeine and hydrocodone | Require CYP2D6 activation | Ultra-rapid metabolizers, including nursing mothers, generate high morphine concentrations |
| Kratom (mitragynine) | Botanical partial mu agonist with stimulant effects at low dose | Seizures, tachycardia, and opioid features in large exposures; often combined with other drugs |
Naloxone: Titration, Not Reversal
Naloxone is a competitive antagonist at mu, kappa, and delta receptors with no intrinsic agonist activity. The therapeutic target is restoration of adequate spontaneous ventilation, not wakefulness.
Dosing Strategy
| Situation | Initial Dose | Rationale |
|---|---|---|
| Adult with suspected dependence, spontaneous pulse | 0.04 to 0.4 mg IV, doubled every 2 to 3 minutes | Avoids precipitated withdrawal while restoring breathing |
| Opioid-naive adult with respiratory arrest | 0.4 to 2 mg IV | Rapid restoration is the priority |
| Cardiac arrest or profound hypoxia | 2 mg IV, repeat as needed | High-potency analogues may need cumulative doses well above 2 mg |
| Child | 0.1 mg/kg IV, IM, or intranasal (maximum about 2 mg per dose) | Children are rarely tolerant |
| No intravenous access | Intramuscular or intranasal | Onset delayed a few minutes; support ventilation meanwhile |
Infusion Arithmetic
When re-sedation is expected, start an hourly infusion at about two-thirds of the total dose that restored ventilation, then titrate.
- Example: 2 mg total was required. Infusion = about 1.3 mg per hour, adjusted to keep respirations adequate without withdrawal.
Consequences of Over-Reversal
Abrupt full reversal in a dependent patient produces catecholamine release with vomiting and aspiration risk, severe agitation, hypertension and tachycardia, and occasionally non-cardiogenic pulmonary edema. In a patient with pain or recent surgery it also unmasks severe pain and can precipitate withdrawal seizures in a neonate.
What Naloxone Does Not Fix
- Tramadol and meperidine neuroexcitation
- Xylazine sedation and bradycardia in an adulterated fentanyl exposure
- Hypoxic brain injury already sustained
- Aspiration pneumonitis or rhabdomyolysis from a prolonged down time
Airway first. Bag-valve-mask ventilation with oxygen corrects hypoxia while naloxone is drawn up, and it prevents the arrest that naloxone alone will not reverse.
Pediatric Single-Dose Lethality
One tablet, film, patch, or teaspoon can be fatal in a toddler. The highest-risk products are methadone solution, buprenorphine film, extended-release oxycodone or morphine, fentanyl patches (including used patches retrieved from a trash can), and diphenoxylate-atropine. Any credible exposure requires emergency evaluation and a monitored observation period, commonly 24 hours for methadone, buprenorphine, extended-release products, and diphenoxylate-atropine.
Testing and Counseling Pitfalls
- Urine immunoassays are calibrated to morphine. Fentanyl, methadone, buprenorphine, tramadol, and novel synthetic opioids are missed. A negative screen in a patient who woke up with naloxone means the assay failed, not that the patient is opioid-free.
- Dedicated fentanyl assays exist but do not detect all analogues.
- Take-home naloxone counseling should cover recognizing slow or absent breathing, giving intranasal or intramuscular naloxone, calling 911 because the effect will wear off, staying with the person, and repeating the dose if breathing does not improve in 2 to 3 minutes.
Poison Center Case: Recurrent Apnea After a "Good Response"
A 34-year-old is found unresponsive with a respiratory rate of 4 and pinpoint pupils. Paramedics give 2 mg intranasal naloxone and the patient wakes, refuses transport, and is convinced by family to come in. Ninety minutes later he is again apneic.
Specialist actions. The CSPI explains that naloxone's 30 to 90 minute duration is shorter than the effect of most opioids, especially methadone, extended-release products, and potent analogues, so re-sedation is expected rather than surprising. The team ventilates, gives a small repeat bolus titrated to breathing, and starts an infusion at roughly two-thirds of the effective dose per hour. Because the patient responded to naloxone but the urine opiate screen is negative, the specialist notes that a synthetic opioid such as fentanyl is the likely agent and warns that xylazine adulteration can leave the patient sedated and bradycardic despite adequate reversal of the opioid component.
A 28-year-old with known opioid use disorder has a respiratory rate of 6, pinpoint pupils, and oxygen saturation of 84%. Which naloxone approach is most appropriate?
A 19-month-old is brought in 3 hours after chewing on a discarded buprenorphine film found in a trash can. She is sleepy but arousable with a respiratory rate of 24. What is the correct disposition guidance?
A 24-year-old taking large daily doses of loperamide to manage opioid withdrawal presents with syncope. The ECG shows a QRS of 130 ms and a QTc of 610 ms with intermittent polymorphic ventricular tachycardia. Which management combination is most appropriate?